TELA Bio, Inc. (TELA): Results of Operations and Financial Condition
TELA Bio, Inc. (TELA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 TELA Bio Reports Second Quarter 2026 Financial Results MALVERN, PA, August 10, 2026 -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results fo
How this was made
The 30-second read
Why it matters
The key tradable disclosure is the withdrawal of full-year 2026 revenue guidance, attributed to OviTex PRS volume declines and ongoing price and mix headwinds, with management signaling cost structure alignment to extend cash runway.
Market read
Investors must reprice TELA’s forward revenue expectations due to the guidance withdrawal and the disclosed Q2 drivers, while monitoring whether PRS performance and ASP/mix stabilize in 2H.
What to watch
Gross margin improved to 72% (tariff refund and lower excess/obsolete charges), and cash was $30.4M at June 30, 2026, which could reduce immediate dilution fears if cost actions are credible.
Second-quarter 2026 revenue declined 4% to $19.3 million, net loss widened to $11.3 million, and TELA Bio withdrew full-year 2026 guidance.
Revenue declined 4% from the prior-year period amid lower OviTex PRS volumes and price and mix headwinds, while loss from operations and net loss increased. The Company withdrew full-year 2026 revenue guidance and reported $30.4 million of cash and cash equivalents against $56.1 million of long-term debt.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Revenue, three months ended June 30, 2026GAAP | $ 19,291 (in thousands) | – | decrease of 4% |
| Cost of revenue (excluding amortization of intangible assets), three months ended June 30, 2026GAAP | 5,253 (in thousands) | – | – |
| Amortization of intangible assets, three months ended June 30, 2026GAAP | 95 (in thousands) | – | – |
| Gross profit, three months ended June 30, 2026GAAP | $ 13,943 (in thousands) | – | – |
| Gross margin, three months ended June 30, 2026GAAP | 72% of revenue | – | – |
| Sales and marketing expense, three months ended June 30, 2026GAAP | 16,442 (in thousands) | – | – |
| General and administrative expense, three months ended June 30, 2026GAAP | 4,061 (in thousands) | – | – |
| Research and development expense, three months ended June 30, 2026GAAP | 2,723 (in thousands) | – | – |
| Total operating expenses, three months ended June 30, 2026GAAP | 23,226 (in thousands) | – | – |
| Loss from operations, three months ended June 30, 2026GAAP | $ (9,283 ) (in thousands) | – | – |
| Interest expense, three months ended June 30, 2026GAAP | (2,076 ) (in thousands) | – | – |
| Other income, three months ended June 30, 2026GAAP | 157 (in thousands) | – | – |
| Total other expense, net, three months ended June 30, 2026GAAP | (1,919 ) (in thousands) | – | – |
| Loss before income tax expense, three months ended June 30, 2026GAAP | (11,202 ) (in thousands) | – | – |
| Income tax expense, three months ended June 30, 2026GAAP | (60 ) (in thousands) | – | – |
| Net loss, three months ended June 30, 2026GAAP | $ (11,262 ) (in thousands) | – | – |
| Net loss per common share, basic and diluted, three months ended June 30, 2026GAAP | $ (0.20 ) | – | – |
| Weighted average common shares outstanding, basic and diluted, three months ended June 30, 2026GAAP | 57,414,360 | – | – |
| Comprehensive loss, three months ended June 30, 2026GAAP | $ (11,263 ) (in thousands) | – | – |
| Revenue, six months ended June 30, 2026GAAP | $ 38,350 (in thousands) | – | – |
| Gross profit, six months ended June 30, 2026GAAP | 26,463 (in thousands) | – | – |
| Total operating expenses, six months ended June 30, 2026GAAP | 46,272 (in thousands) | – | – |
| Loss from operations, six months ended June 30, 2026GAAP | (19,809 ) (in thousands) | – | – |
| Net loss, six months ended June 30, 2026GAAP | $ (23,535 ) (in thousands) | – | – |
| Net loss per common share, basic and diluted, six months ended June 30, 2026GAAP | $ (0.41 ) | – | – |
full year 2026 outlook
- NoteThe Company has withdrawn full-year guidance and will provide an update in the future.
What drove it
- International revenue growth of 26% over the prior year period.
- OviTex unit volume growth of 12% over the prior year period.
- LiquiFix revenue grew 39% over the prior-year period.
- The revenue decrease was primarily driven by a decline in OviTex PRS volumes and price mix headwinds, partially offset by growing international sales.
- The increase in gross margin was primarily due to a tariff refund and a lower charge for excess and obsolete inventory as a percentage of revenue.
- The Company returned to a sales structure designed to reinforce cross-selling among field teams.
- Heather Getz was appointed Chief Executive Officer and Director, effective August 4, 2026.
Concerns
- OviTex PRS volumes declined during the second quarter of 2026.
- The Company cited continued price and mix headwinds in hernia procedures.
- The Company cited competitive dynamics of bundling from its largest competitors.
- Loss from operations was $9.3 million in the second quarter of 2026, compared to $9.1 million in the same period in 2025.
- Net loss was $11.3 million in the second quarter of 2026, compared to a net loss of $9.9 million in the same period in 2025.
- The Company withdrew full-year 2026 revenue guidance.
- Cash and cash equivalents were $30.4 million at June 30, 2026, while long-term debt was 56,081 (in thousands).
What to watch
- OviTex PRS performance in the second half of 2026.
- Whether hernia market-share gains and stabilizing ASP and procedure mix translate into top-line growth.
- International revenue momentum and LiquiFix revenue growth.
- Productivity progress among newer territory managers.
- Actions to extend cash runway and align the cost structure with the top line.
- The Company's future update to full-year 2026 guidance.
Balance sheet and cash flow
- Cash and cash equivalents were $ 30,424 (in thousands) at June 30, 2026, compared to $ 50,845 (in thousands) at December 31, 2025.
- Accounts receivable, net of allowances of $522 and $287, were 9,637 (in thousands) at June 30, 2026, compared to 10,347 (in thousands) at December 31, 2025.
- Inventory was 11,059 (in thousands) at June 30, 2026, compared to 11,016 (in thousands) at December 31, 2025.
- Total current assets were 54,491 (in thousands) at June 30, 2026, compared to 75,581 (in thousands) at December 31, 2025.
- Total assets were $ 59,738 (in thousands) at June 30, 2026, compared to $ 81,418 (in thousands) at December 31, 2025.
- Total current liabilities were 18,218 (in thousands) at June 30, 2026, compared to 17,975 (in thousands) at December 31, 2025.
- Long-term debt was 56,081 (in thousands) at June 30, 2026, compared to 55,653 (in thousands) at December 31, 2025.
- Total liabilities were 75,604 (in thousands) at June 30, 2026, compared to 75,105 (in thousands) at December 31, 2025.
- Total stockholders’ (deficit) equity was (15,866 ) (in thousands) at June 30, 2026, compared to 6,313 (in thousands) at December 31, 2025.
Analysis
TELA Bio reported second-quarter revenue of $19.3 million, a decrease of 4% from $20.2 million in the second quarter of 2025. Management attributed the decline primarily to lower OviTex PRS volumes and price mix headwinds, partly offset by international sales growth. The release cited international revenue growth of 26%, OviTex unit volume growth of 12%, and LiquiFix revenue growth of 39% over the prior-year period, indicating that the reported shortfall was concentrated in PRS rather than across all cited commercial indicators.
Gross profit was $13.9 million, compared with $14.1 million, while gross margin increased to 72% of revenue from 70% of revenue. The Company attributed the margin increase to a tariff refund and a lower charge for excess and obsolete inventory as a percentage of revenue. Total operating expenses were $23.2 million in both periods, with higher meeting and training costs and professional fees largely offset by lower compensation and benefits, commission expense, and study costs.
Profitability remained under pressure. Loss from operations was $9.3 million versus $9.1 million in the prior-year period, and net loss was $11.3 million versus $9.9 million. Interest expense was $(2,076 ) (in thousands), compared with $(1,188 ) (in thousands). For the six months ended June 30, 2026, revenue was $38,350 (in thousands), loss from operations was $(19,809 ) (in thousands), and net loss was $(23,535 ) (in thousands).
Liquidity and capital structure are central areas of attention. Cash and cash equivalents were $30.4 million at June 30, 2026, compared with $50.8 million at December 31, 2025, while long-term debt was 56,081 (in thousands). Total stockholders’ (deficit) equity was $(15,866 ) (in thousands). Management said it will take decisive action to extend cash runway and better align its cost structure with its top line.
The Company withdrew full-year 2026 guidance and said it will provide an update in the future. Management's stated second-half priorities are improving PRS performance, accelerating hernia market-share gains, raising commercial productivity, and restoring sustainable top-line growth. The key reported operational evidence to monitor is whether the cited stabilization in ASP and procedure mix, international momentum, and field-team productivity offset the PRS volume decline.
Management, verbatim
Unfortunately, the financial performance of the business does not reflect the superiority of the portfolio. Our second quarter revenue was negatively impacted by a decline in OviTex PRS volumes and continued price and mix headwinds in hernia procedures. In response, we have returned to a sales structure designed to reinforce cross-selling among our field teams, and with a clear focus on returning to growth in the second half the year.
Heather Getz, Chief Executive Officer
Given the confluence of these dynamics, we are withdrawing our full year 2026 revenue guidance as I fully assess the business and strategic direction.
Heather Getz, Chief Executive Officer
Not in the filing
stated, not guessed- Prior-quarter comparisons for reported income-statement metrics.
- Non-GAAP financial measures, including non-GAAP operating income, non-GAAP net income, and non-GAAP EPS.
- Operating cash flow.
- Free cash flow.
- Capital-return activity, including share repurchases and dividends.
- Quantified full-year 2026 guidance for revenue, gross margin, operating expenses, tax rate, or other metrics.
- Revenue by product, geography, or operating segment.
- Prior guidance was not provided, so no comparison of actual results against prior guidance is available.
AlphaAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
TELA Bio reported Q2 2026 results and announced a new CEO (Heather Getz) effective August 4, 2026, alongside a strategic sales-structure change.
Ticker impact
TELA withdrew full-year 2026 revenue guidance after Q2 revenue fell to $19.3M, driven by lower OviTex PRS volumes and price/mix headwinds.
Likely downside bias and elevated volatility until management updates full-year outlook and PRS performance stabilizes.
The filing discloses a concrete guidance withdrawal plus Q2 underperformance drivers (OviTex PRS volume decline, price/mix headwinds) and cost alignment intent, which typically pressures valuation multiples for commercial-stage medtech.
Market effects
Soft-tissue reconstruction peers may face read-across risk if investors interpret PRS volume weakness as demand or competitive share pressure.
International revenue grew 26% YoY, which may partially offset concerns about Europe versus US procedure dynamics.
Limited broader market impact; primarily company-specific sentiment for small-cap medtech.
Counterpoint
International growth (26% YoY) and OviTex unit volume growth for OviTex (12% for OviTex unit volume) suggest underlying demand and share gains may be real, with the guidance withdrawal reflecting timing rather than structural deterioration.
Key entities
- companyTELA Bio, Inc.
Commercial-stage medical technology company reporting Q2 2026 financial results and withdrawing full-year 2026 guidance.
- executiveHeather Getz
Appointed CEO and Director effective August 4, 2026; cited PRS performance issues and competitive bundling dynamics.
